Prima BioMed to Present at the 15th Annual BIO CEO & Investor Conference
(firmenpresse) - SYDNEY, AUSTRALIA -- (Marketwire) -- 01/28/13 -- Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima", "the Company") has announced today that Matthew Lehman, its Chief Executive Officer, will present at the 15th Annual BIO CEO & Investor Conference on Tuesday, 12 February 2013 at 11:30am Eastern US Time in New York, NY. Mr. Lehman will provide an overview of the Company and its corporate activities.
The presentation will be a live audio webcast and may be accessed by visiting Prima BioMed's website at . A replay of the webcast will be available for 90 days following the presentation.
Prima BioMed is a globally active biotechnology company. As a leader in personalized bio-therapeutic products for cancer, Prima is dedicated to leveraging its current technology and expertise to develop innovative treatment options for patients and to maximize value to shareholders. Prima's lead product is CVac™, an autologous dendritic cell product currently in clinical trials for ovarian cancer patients who are in remission.
Ms. Jessica Brown
Prima BioMed Ltd.
+1 (919) 710-9061
Mr. James Moses
Mandate Corporate
+61 (0) 420 991 574
Mr. Axel Muhlhaus
edicto GmbH
+49 (0) 69 905505-52
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 28.01.2013 - 22:30 Uhr
Sprache: Deutsch
News-ID 223684
Anzahl Zeichen: 0
contact information:
Town:
SYDNEY, AUSTRALIA
Kategorie:
Biotech
Diese Pressemitteilung wurde bisher 235 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Prima BioMed to Present at the 15th Annual BIO CEO & Investor Conference"
steht unter der journalistisch-redaktionellen Verantwortung von
Prima BioMed (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
